Therapeutic Hypothermia Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Therapeutic Hypothermia Systems Market is projected to expand from USD 311.45 Million in 2025 to USD 457.27 Million by 2031, achieving a compound annual growth rate of 6.61%. These specialized medical devices are designed to lower a patient's body temperature to a therapeutic level, mitigating the risk of ischemic injury to the brain and vital organs after periods of reduced blood flow. A major catalyst for this market is the increasing incidence of cardiac arrest and neonatal hypoxic-ischemic encephalopathy, which creates a strong need for dependable temperature management to improve survival rates and neurological outcomes. Highlighting this urgent need, the Sudden Cardiac Arrest Foundation reported in 2025 that American Heart Association data indicates approximately 350,000 out-of-hospital cardiac arrests take place annually in the United States, emphasizing the necessity for effective post-resuscitation care.

Despite the clear clinical benefits, market growth faces significant hurdles due to the high purchase price of advanced cooling units and the need for specialized training to handle potential complications. These financial and operational obstacles frequently hinder the broad implementation of these technologies, especially within healthcare facilities that have limited resources or smaller hospital settings. Consequently, while the demand for improved patient outcomes drives interest, budget constraints and the complexity of deployment continue to restrict widespread adoption in certain sectors.

Market Drivers

The increasing global frequency of cardiac arrest acts as a major driver for the therapeutic hypothermia systems market, creating a critical need for advanced targeted temperature management (TTM) to limit neurological injury. Upon the return of spontaneous circulation following cardiac arrest, patients are often at risk of reperfusion injury, a condition that cooling systems mitigate by lowering cerebral metabolic rates. This clinical necessity fuels the adoption of both intravascular and surface cooling units within intensive care environments to enhance post-resuscitation treatment. The magnitude of this demand is illustrated by the Sudden Cardiac Arrest Foundation's January 2025 'Latest Statistics' report, which noted that 137,119 out-of-hospital cardiac arrest events were recorded in the United States' CARES registry during 2024, demonstrating a significant addressable market for technologies capable of maximizing patient survival.

Concurrently, the rising prevalence of neonatal encephalopathy and birth asphyxia is compelling neonatal intensive care units to widely adopt specialized cooling devices. Therapeutic hypothermia has become the standard treatment for newborns with hypoxic-ischemic encephalopathy (HIE) because it substantially lowers the likelihood of permanent cognitive and motor impairments. According to the 'State of Neonatal HIE' review by Hope for HIE in June 2025, approximately 1.2 million infants worldwide develop this condition annually, ensuring a steady demand for precise neonatal cooling solutions. This clinical requirement is driving commercial growth for manufacturers; for example, BrainCool AB reported in February 2025 that it delivered 39 systems in the fourth quarter of 2024, achieving record quarterly sales of SEK 12.0 million, which underscores the rapid uptake of these essential systems in critical care settings.

Market Challenges

The substantial acquisition costs associated with advanced cooling units, along with the requirement for specialized personnel training, represent a significant obstacle to the growth of the Global Therapeutic Hypothermia Systems Market. These financial and operational demands restrict the capacity of healthcare institutions, especially those in developing regions or with limited budgets, to incorporate these devices into standard care protocols. When hospitals must prioritize their spending, the heavy upfront investment required for temperature management systems frequently results in postponement in favor of equipment that is more versatile or immediately essential. This reluctance creates a direct link to slower market penetration and dampened overall growth rates.

Moreover, the challenging economic landscape for healthcare providers has further cemented this hesitation regarding capital-intensive investments. A 2025 report from the American Hospital Association indicated that 94% of healthcare administrators anticipated delaying equipment upgrades to cope with persistent financial pressures. This statistic highlights the intense fiscal difficulties hospitals face, where increasing operational expenses and finite capital reserves mandate a conservative procurement strategy. As a result, even though the clinical advantages of therapeutic hypothermia are well understood, the combination of high device pricing and the resource burden of necessary training programs effectively limits widespread implementation.

Market Trends

The market is observing a distinct shift toward non-invasive surface cooling methods to reduce the procedural risks linked to invasive intravascular catheters. Advanced surface systems enable medical staff to begin temperature management immediately, avoiding the delays and infection risks associated with establishing central venous access. This preference for external modalities is evident in the financial results of leading manufacturers in the sector; for instance, Gentherm reported in its February 2025 '2024 Fourth Quarter and Full Year Results' that its Medical segment revenue rose to $49.8 million in 2024, an 8.1% increase year-over-year, largely due to strong demand for surface thermal management solutions. This growth indicates a sustained pivot toward non-invasive technologies for critical care environments.

At the same time, the emergence of portable pre-hospital cooling systems is revolutionizing early intervention strategies for stroke and cardiac arrest. By employing battery-operated or intranasal technologies, emergency responders can induce neuroprotective cooling before a patient reaches the hospital, thereby extending the critical therapeutic window. This trend is bolstered by ongoing clinical research into mobile devices designed for selective brain cooling in the field. Notably, BrainCool AB announced in a July 2024 press release that the first patient had been enrolled in the pivotal COTTIS 2 study to assess the RhinoChill portable intranasal cooling system during thrombectomy procedures, marking a significant step in bridging the gap between ambulance transport and intensive care.

Key Players Profiled in the Therapeutic Hypothermia Systems Market

• Belmont Medical Technologies
• BrainCool AB
• ZOLL Medical Corporation
• Becton, Dickinson, and Company
• Stryker Corporation
• EM-MED Sp. z o.o.
• Life Recovery Systems
• Dragerwerk AG & Co. KGaA
• Terumo Cardiovascular Systems Corporation
• pfm medical gmbh

Report Scope

In this report, the Global Therapeutic Hypothermia Systems Market has been segmented into the following categories:

Therapeutic Hypothermia Systems Market, by Product:

• Cooling Catheters
• Water Blankets
• Cool Caps
• Others

Therapeutic Hypothermia Systems Market, by Application:

• Neurology
• Cardiology
• Neonatal Care
• Others

Therapeutic Hypothermia Systems Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Hypothermia Systems Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.